

S 2022

Ending the Diagnostic Odyssey Act of 2021

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Jun 10, 2021

Current Status: Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S4

Latest Action: Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S4046-4047) (Jun 10, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/2022>

Sponsor

Name: Sen. Collins, Susan M. [R-ME]

Party: Republican • **State:** ME • **Chamber:** Senate

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Kelly, Mark [D-AZ]	D · AZ		Jun 10, 2021
Sen. Menendez, Robert [D-NJ]	D · NJ		Jun 10, 2021
Sen. Smith, Tina [D-MN]	D · MN		Dec 6, 2021

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Jun 10, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Ending the Diagnostic Odyssey Act of 2021

This bill allows state Medicaid programs to cover whole genome sequencing services for certain individuals.

Specifically, states may cover such services for individuals under the age of 21 (or a lower age, if the state chooses) and for former foster youth under the age of 26 who (1) have been referred or admitted to an intensive care unit or seen by a medical specialist for a suspected genetic or undiagnosed disease, or (2) are suspected by a medical specialist to have a neonatal- or pediatric-onset genetic disease.

The Centers for Medicare & Medicaid Services may award grants to assist states in developing plans to cover such services.

Actions Timeline

- **Jun 10, 2021:** Introduced in Senate
- **Jun 10, 2021:** Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S4046-4047)